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Host Defense (Antimicrobial) Peptide, Human
b-Defensin-3, Improves the Function of the Epithelial
Tight-Junction Barrier in Human Keratinocytes
Chanisa Kiatsurayanon1,2, Franc¸ois Niyonsaba1, Rithee Smithrithee1,2, Toshihiro Akiyama1,2, Hiroko Ushio1,
Mutsuko Hara1, Ko Okumura1, Shigaku Ikeda1,2 and Hideoki Ogawa1
Human b-defensins (hBDs) are host defense peptides that not only exhibit microbicidal properties but also
stimulate various cellular activities, including keratinocyte proliferation, migration, and wound healing. hBDs are
overexpressed in the skin in cases of psoriasis but are downregulated in atopic dermatitis skin, although both
diseases are associated with stratum corneum barrier defects. Because the tight-junction (TJ) barrier is also
dysfunctional in both atopic dermatitis and psoriasis patients, we hypothesized that hBDs may regulate the TJ
barrier function in keratinocytes. We observed that, among the hBDs tested, only hBD-3 increased the expression
of several claudins and their localization along the cell–cell borders. In addition, hBD-3 elevated the
transepithelial electrical resistance and reduced the paracellular permeability of keratinocyte layers, and this
effect was reversed by the claudin inhibitor ochratoxin A, CCR6 antibody, and CCR6 small interfering RNA.
Moreover, hBD-3 enhanced the activation of Rac1, atypical protein kinase C, glycogen synthase kinase-3, and
phosphatidylinositol 3 kinase, which are required for the hBD-3-mediated regulation of the TJ barrier function, as
evidenced by the effects of their respective inhibitors. Collectively, our findings provide evidence regarding the
contribution of host defense peptides to the innate immunity of skin by regulating TJ barrier function, in addition
to their antimicrobial and other immunomodulatory activities.
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INTRODUCTION
The skin upholds homeostasis by preventing water loss via
evaporation and precluding the penetration of exogenous
substances due to its structural integrity and secretion of
complement proteins and cytokines/chemokines (Baroni
et al., 2012). As an antimicrobial barrier, the skin generates
a number of antimicrobial or host defense peptides (HDPs).
Besides their antimicrobial activities, HDPs exhibit a wide
variety of immunomodulatory functions, including promoting
chemotaxis, stimulating chemokine/cytokine production,
suppressing proinflammatory responses, and inducing cell
proliferation, angiogenesis, and wound healing (Niyonsaba
et al., 2006, 2009).
The major HDPs found in human skin include the human
b-defensins (hBDs) and LL-37. The hBDs are characterized by
the presence of three family-specific disulfide bonds and are
produced mainly by the epithelia of several organs, including
the skin (Ganz, 2003; Niyonsaba et al., 2006). Four hBDs,
hBD-1 through hBD-4, have been identified in human skin to
date. hBD-1 is constitutively expressed by various epithelial
tissues, particularly in the skin, urogenital, and respiratory
tissues (Fulton et al., 1997; Ali et al., 2001). hBD-2 was
initially identified in psoriatic lesions and was later found in
keratinocytes (Harder et al., 1997; Liu et al., 2002). hBD-3
was first isolated from lesional scales, and although it is a
psoriatic product, it is also abundant in nonepithelial tissues
(Harder et al., 2001). Finally, hBD-4 has been identified in the
skin only at the mRNA level (Garcia et al., 2001) and is
inducible in differentiated keratinocytes (Harder et al., 2004).
In the skin, hBDs have been reported to induce keratinocyte
migration, proliferation, and cytokine/chemokine production
and to accelerate wound healing (Sorensen et al., 2003;
Niyonsaba et al., 2005, 2007). Skin-derived HDPs are
closely associated with skin diseases. For instance, the expres-
sion of hBDs and LL-37 is upregulated in cases of wounding,
acne vulgaris, and psoriasis (Sorensen et al., 2003; Niyonsaba
et al., 2005, 2007); on the contrary, their expression is
downregulated in atopic dermatitis (AD) (Ong et al., 2002;
Nomura et al., 2003). This finding explains why patients
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with AD but not psoriasis often demonstrate increased
susceptibility to infections.
It was recently demonstrated that uninvolved AD skin, in
contrast to psoriatic skin, has a markedly reduced content of
tight-junction (TJ) proteins, resulting in barrier dysfunction and
immune dysregulation in AD patients (De Benedetto et al.,
2011). TJs are cell–cell junctions that form the major barrier
controlling the paracellular permeability of water, ions, and
solutes across epithelial cell sheets (Kirschner et al., 2013).
TJs mainly consist of claudins, occludin, junctional adhesion
molecules, and the zonula occludens (Niessen, 2007).
Claudins are essential for the regulation of TJ function either
by enhancing the barrier, e.g., claudin-1, which is crucial
for tightening the epithelial barrier (Furuse et al., 2002)
or disrupting the barrier, e.g., claudin-2, which attenuates
the tightness of the epithelial barrier (Furuse et al., 2001).
Although both psoriasis and AD are associated with an
impaired stratum corneum barrier, the TJ protein expression
is downregulated in AD (De Benedetto et al., 2011), but it is
normal, increased, or decreased in psoriasis (Itoh et al., 2005;
Peltonen et al., 2007; Kirschner et al., 2009). Because the
expression of hBDs is reduced in AD but increased in
psoriasis, our objective was to investigate the effects of
hBDs on the TJ barrier function in skin and to examine the
possible underlying mechanisms of the effects.
Here, we demonstrated that hBD-3 enhanced the expres-
sion and cell membrane localization of certain claudins and
elevated transepithelial electrical resistance (TER) while redu-
cing paracellular permeability in keratinocyte layers, through
CCR6 signaling. In addition, hBD-3 activated the Rac1,
atypical atypical protein kinase C (aPKC), glycogen synthase
kinase (GSK)-3, and phosphatidylinositol 3 kinase (PI3K)
pathways, which are necessary for the hBD-3-mediated
regulation of the TJ barrier function. These observations
provide evidence of the contribution of HDPs to the innate
immunity of the skin through regulating the TJ barrier function.
RESULTS
hBD-3 increases the expression and membrane localization of TJ
proteins
Among the four hBDs, only hBD-3 significantly and dose-
dependently upregulated (from 4- to 60-fold) the expression of
claudin-1 through claudin-5, claudin-9, claudin-11, claudin-
14 through claudin-17, claudin-20, claudin-23, and claudin-
25 (Figure 1a). In contrast, hBD-3 did not affect the expression
of occludin, cadherin, and zonula occludens (data not shown),
suggesting that it is a selective effector. Unexpectedly, hBD-1,
-2, and -4, even at doses as high as 40mg ml 1, did not
increase the expression of the TJ proteins tested (data not
shown). Western blot analysis revealed that only claudin-1,
claudin-3, claudin-4, claudin-14, and claudin-23 were
enhanced at the protein level following hBD-3 stimulation
(Figure 1b). Because the cellular localization of TJ proteins is
essential for functional TJ formation, the effect of hBD-3 on
cellular distribution of claudins was examined. hBD-3
induced a widespread localization of claudin-1, claudin-3,
claudin-4, and claudin-14, and a slight increase of claudin-23
at the cell–cell borders (Figure 2). Thus, the selective effect of
hBD-3 on certain claudins implies the importance of these
molecules in the hBD-3-mediated regulation of TJ barrier
function.
Ochratoxin A blocks hBD-3-mediated changes in the TJ barrier
function
To examine whether the hBD-3-mediated changes in claudin
localization were associated with the TJ function, we assessed
the TJ barrier function parameters, TER, and paracellular
permeability of FITC–dextran (Matter and Balda, 2003; Yuki
et al., 2007). Upon stimulation with hBD-3, the TER of
keratinocyte layers dose- and time-dependently increased.
The highest TER value was observed at 72 hours, and it then
gradually declined (Figure 3a). Furthermore, as shown in
Figure 3b, control keratinocyte layers exposed to the vehicle
exhibited high levels of 4 kDa FITC–dextran flux from
the apical compartment to the basolateral compartment.
However, the paracellular flux of FITC–dextran through layers
treated with hBD-3 was significantly decreased. Paracellular
flux following a 72-hour treatment was maximally inhibited,
and it then progressively increased. This indicates that hBD-3
improves the formation and function of the TJ barrier.
Interestingly, hBD-1, hBD-2, and hBD-4 neither markedly
affected the membrane localization of claudins (Supplemen-
tary Figure S1 online), nor increased TJ barrier function
as assessed by TER and paracellular flux (Supplementary
Figure S2 online).
Because ochratoxin A is able to induce a decrease in the TJ
barrier function by removing claudins (McLaughlin et al.,
2004; Lambert et al., 2007), keratinocyte layers were treated
with ochratoxin A, and the TER and paracellular flux were
assessed. Ochratoxin A treatment caused a reduced TER and
elevated flux of FITC–dextran in hBD-3-stimulated keratino-
cyte layers (Figure 3c). This suggests an association between
hBD-3-mediated TJ barrier function and reduced expression of
claudins.
hBD-3-induced improvement of TJ barrier function is mediated
through CCR6
Because hBD-3 functions through CCR6 activation (Wu et al.,
2003; Nagaoka et al., 2008), we tested involvement of CCR6
in the hBD-3-mediated regulation of TJ function by treating
keratinocyte layers with CCR6-neutralizing antibody or trans-
fecting cells with CCR6 small interfering RNA to knockdown
CCR6 receptor (Supplementary Figure S3 online). As pictured
in Figure 4a and b, both CCR6-neutralizing antibody and
CCR6 small interfering RNA markedly reduced TER and
increased the paracellular permeability to the baseline in
hBD-3-stimulated layers, demonstrating involvement of CCR6
in hBD-3-mediated improvement of TJ barrier function.
hBD-3 induces activation of aPKC and Rac1, which are
necessary for the TJ barrier function
The aPKC family has two isoforms, aPKCz and aPKCi/l, which
are expressed in keratinocytes and are associated with TJ
proteins (Helfrich et al., 2007). Thus, we investigated the
possible role of these kinases in hBD-3-mediated regulation of
TJ barrier function. We observed that the phosphorylation of
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aPKCz/l was markedly enhanced in keratinocytes stimulated
with hBD-3 for 8 hours (Figure 5a). This activation was
necessary for the hBD-3-improved TJ barrier function, because
treatment of keratinocyte layers with GF 109203X, a pan-PKC
inhibitor that hampers increases in the TER (Turner et al.,
1999), notably suppressed hBD-3-induced elevation of the
TER and also increased the flux of FITC–dextran (Figure 5b).
Furthermore, as aPKC signaling is activated by guanosine
triphosphate (GTP)-bound Rac1-induced protein phosphoryla-
tion (Chen and Macara, 2005) and because dominant-negative
Rac1 and kinase-dead aPKC inhibit TJ functions (Mertens
et al., 2005; Helfrich et al., 2007), we investigated whether
hBD-3 regulates TJ barrier function by activating GTP-Rac1.
First, Rac1 pull-down assays revealed that hBD-3 stimulation
increased the level of activated GTP-Rac1, compared with that
of control samples, in as little as 5 minutes, and this effect was
sustained for up to 15 minutes (Figure 5c). GTP-Rac1 is indeed
required for the TJ barrier function because blockade of Rac1
activation using NSC23766 (Baumer et al., 2009), resulted in
reduced TER and enhanced paracellular flux of FITC–dextran
in hBD-3-stimulated keratinocyte layers (Figure 5d).
hBD-3 regulates TJ barrier function through activating GSK-3
and PI3K
GSK-3 is implicated in the expression of TJ proteins and the
maintenance of the TJ barrier function (Doble and Woodgett,
2003). We therefore hypothesized that hBD-3 might also
activate GSK-3 to regulate the TJ barrier function. The results
revealed a strong GSK-3a/b (Y279/Y216) signal following a
2-hour stimulation with hBD-3, and GSK-3 activation was
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Figure 1. Effects of human b-defensins (hBDs) on the expression of tight-junction (TJ) mRNAs and proteins in keratinocytes. (a) Keratinocytes were
incubated with 5–20mg ml1 of hBDs or medium alone for 24–48 hours. Following the incubation, total RNA was extracted and reverse-transcribed into
complementary DNA, and quantitative real-time reverse-transcriptase–PCR was performed. The values represent fold-increases in gene expression relative to those
of controls stimulated with medium alone (Med). *Po0.05, **Po0.01, ***Po0.001, n¼5. (b) Keratinocytes were stimulated with 2.5–20mg ml1 of hBD-3 or the
diluent (Med) for 48 hours. The levels of claudin-1, claudin-3, claudin-4, claudin-14, and claudin-23 in cell lysates were determined by western blot.
The results of one representative experiment of three separate experiments yielding similar results are shown.
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sustained for up to 8 hours (Figure 6a). This activation was
required for the hBD-3-mediated regulation of the TJ barrier
function, as confirmed by the effect of the GSK-3 inhibitor, SB
415286 (Severson et al., 2010), that drastically decreased TER,
while markedly increasing the paracellular flux (Figure 6b) in
hBD-3-stimulated keratinocyte layers.
Moreover, because the PI3K pathway participates in sealing
the TJ by improving the TER and TJ protein expression
(Gonzalez-Mariscal et al., 2008), we envisaged that hBD-3
might also mediate PI3K activation. Figure 6c shows that
during stimulation with hBD-3, the PI3K (p85/p55) signal was
strongly increased at 0.5 hours and then gradually decreased.
Treatment of keratinocyte layers with wortmannin disrupted
the hBD-3-mediated improvement of the barrier function, as
demonstrated by the reduced TER and increased paracellular
flux (Figure 6d), implying that hBD-3 regulates paracellular
permeability through activating PI3K.
DISCUSSION
A recent report that impaired TJ protein expression contributes
to the barrier dysfunction in AD (De Benedetto et al., 2011), in
contrast to psoriasis, in which the expression of TJ proteins is
normal, increased, or decreased (Itoh et al., 2005; Peltonen
et al., 2007; Kirschner et al., 2009) incited us to hypothesize
that the differential expression of hBDs in psoriasis and AD
may have a key role in regulating the TJ barrier function. We
demonstrated that hBD-3 selectively increased the expression
and membrane localization of certain claudins, enhanced the
TER, and reduced paracellular flux in keratinocyte layers. This
enhancement of the TJ barrier function was controlled by
CCR6, aPKC, GTP-Rac1, GSK-3, and PI3K pathways.
The claudin family provides the most important components
of TJs, with more than 24 members that determine TJ resi-
stance and permeability (Van Itallie and Anderson, 2006). We
showed that hBD-3 increased the gene expression of claudins,
which have been found in keratinocytes (Brandner et al.,
2002; Watson et al., 2007; Brandner, 2009; De Benedetto
et al., 2011), and demonstrated that keratinocytes also express
claudin-20 and claudin-25. Among these claudins, only
claudin-1, claudin-3, claudin-4, claudin-14, and claudin-23
were selectively enhanced at the protein level, and their
localization at cell–cell borders was also increased, suggesting
the importance of these claudins in the TJ barrier function.
Our results corroborate previous findings that claudin-1,
claudin-4, and claudin-14 improve TJ function (Anderson
and Van Itallie, 2009), and that claudin-3 and claudin-23
also have a crucial role in TJ regulation (Wolburg et al., 2003;
Milatz et al., 2010; De Benedetto et al., 2011). In contrast,
hBD-3 had no effect on the protein expression of claudin-2,
claudin-6, and claudin-10 (data not shown), which disrupt the
TJ barrier function (Turksen and Troy, 2002; Anderson and
Van Itallie, 2009). This suggests that hBD-3 contributes to the
regulation of the epidermal barrier function. Notably, the
physiological function of the hBD-3-induced upregulation of
claudins was confirmed by the increased TER and reduced
paracellular flux, and these effects were reversed by a claudin
inhibitor.
Besides differential production of HDPs, psoriasis and AD
are also characterized by a specific difference in the profile of
cytokines/chemokines (Wilsmann-Theis et al., 2008), which
are involved in the TJ regulation. For instance, IL-4, IL-13, and
eotaxin that are overexpressed in AD attenuate the TJ barrier
function (Capaldo and Nusrat, 2009; Jamaluddin et al., 2009),
implying that dysregulated TJ function in AD might be a result
of these cytokines/chemokines. In contrast, IFN-g and tumor
necrosis factor-a that are overexpressed in psoriasis improve
the TJ function (Capaldo and Nusrat, 2009). However,
because these cytokines also downregulate the TJ function
(Capaldo and Nusrat, 2009), there are still discrepancies in the
TJ regulation in psoriasis. Our previously unreported finding
proposes that dysregulated hBD-3 expression might play a key
role in the TJ defect observed in both AD and psoriasis.
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Medium hBD-3
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Figure 2. Human b-defensin-3 (hBD-3) enhances immunolocalization of
certain claudins. Keratinocytes grown to confluence on collagen I-coated
chamber slides were stimulated with 20mg ml1 hBD-3 for 72 hours. The cells
were then fixed in methanol, processed for immunofluorescence with
antibodies against claudins overnight, and then visualized using confocal laser
scanning microscopy. The results of one representative experiment of three
separate experiments yielding similar results are shown. Scale bar¼ 10mm.
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Although hBD-1 through hBD-4 activate keratinocytes, we
unexpectedly found that only hBD-3 regulates the TJ barrier
function. One of the reasonable interpretations for this
observation is the possibility that hBD-3 may interact with
certain specific proteins in keratinocytes, which other hBDs
cannot bind. For instance, although hBDs induce cell
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Figure 3. Human b-defensin-3 (hBD-3) enhances the tight-junction (TJ) barrier function. (a, b) Keratinocyte layers were stimulated with 2.5–20mg ml1 hBD-3,
and the transepithelial electrical resistance (TER) and paracellular flux were determined as described in Materials and Methods. The values obtained
using stimulated and nonstimulated cells were compared (Med). *Po0.05, **Po0.01, ***Po0.001, ****Po0.0001, n¼ 5. (c) Keratinocyte layers were pre-treated
with 0.5 and 1 nM ochratoxin A (OTA) or 0.1% DMSO for 24 hours, stimulated with 20mg ml1 hBD-3 or diluent for 72 hours, and then the TER and the
paracellular flux were measured. The values obtained using stimulated and nonstimulated cells (Med, OTA) or with the presence and absence of inhibitor were
compared. **Po0.01, ***Po0.001, n¼5.
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migration through CCR2, CCR6, and EGFR (Wu et al., 2003;
Niyonsaba et al., 2007; Rohrl et al., 2010), only hBD-3 but not
other hBDs inhibits neutrophil apoptosis via CCR6 (Nagaoka
et al., 2008). This incited us to explore the role of CCR6 in
hBD-3-mediated TJ barrier function regulation. Neutralizing
and knocking down CCR6 suppressed hBD-3-induced impro-
vement of TJ barrier function, confirming the requirement of
this receptor in hBD-3 regulation of TJ function. However,
because hBD-3 is a very strong cationic peptide (with a net
charge of þ11) compared with other hBDs, one could not
exclude the possibility that hBD-3 might also efficiently act
upon nonselective membrane receptors to activate keratino-
cytes, as reported for many cationic peptides (Ferry et al.,
2002).
To further investigate the molecular mechanisms by which
hBD-3 increases the TJ barrier function, we focused on aPKC,
Rac1, GSK-3, and PI3K that regulate TJ formation (Mertens
et al., 2005; Helfrich et al., 2007; Gonzalez-Mariscal et al.,
2008; Severson et al., 2010). The overexpression of aPKC is
sufficient for TJ formation in keratinocytes in which TJ
formation is defective, and TJ formation is regulated by the
polarity protein complex Par3/Par6/aPKC that functions
downstream of Rac1 (Mertens et al., 2005). Furthermore,
low GTP-Rac1 levels and reduced aPKC activity suppress
the maturation of TJs (Mertens et al., 2005), and UVB-irradiation
of skin causes the deterioration of TJ functionality, which is
accompanied by the downregulation of GTP-Rac1 and aPKC
(Yuki et al., 2011).
Recently, the activity of GSK-3 has also been implicated
in regulating the TJ barrier function. Although GSK-3 was
generally considered a constitutive active enzyme, only
regulated by inhibition through its phosphorylation at S21/S9
(Doble and Woodgett, 2003), recent reports have indicated
that phosphorylation of GSK-a/b at Y279/Y216 leads to GSK-3
activation (Bhat et al., 2000; Sayas et al., 2002). Therefore, our
findings that hBD-3 increased the phosphorylation of GSK-a/b
at Y279/Y216 but not S21/S9 (data not shown), and that the
inhibition of GSK-3 activity reversed TJ barrier function
suggested that hBD-3 improves TJ function through GSK-3
activation. This is consistent with studies showing that
inhibiting GSK-a/b increases epithelial permeability, and this
is attributable to the downregulation of TJ protein expression
(Bachelder et al., 2005; Severson et al., 2010).
Because of evidence implicating PI3K in TJ assembly, the
role of the PI3K signaling pathway in the hBD-3-mediated
regulation of the TJ barrier function was studied. Our finding is
supported by a study showing the requirement for PI3K in
Der p2-induced claudin-2 expression in lung alveolar cells
0
200
400
600
800
1,000
0
200
400
600
800
1,000
0
20
40
60
80
100
*
*
*
TE
R
 (Ω
 
cm
2 )
TE
R
 (Ω
 
cm
2 )
4 
kD
a 
FI
TC
–d
ex
tra
n 
(μg
 m
l–1
)
4 
kD
a 
FI
TC
–d
ex
tra
n 
(μg
 m
l–1
)
150
50
0
100
**
**
**
*
*
**
*
*
*
Me
d
An
ti-C
CR
6
hB
D-
3
hB
D-
3+
an
ti-C
CR
6
Me
d
Me
d
Ctr
l si
RN
A
Ctr
l si
RN
A
CC
R6
 siR
NA Me
d
Ctr
l si
RN
A
Ctr
l si
RN
A
CC
R6
 siR
NA
An
ti-C
CR
6
hB
D-
3
hB
D-
3+
an
ti-C
CR
6
hBD-3 hBD-3
Figure 4. Human b-defensin-3 (hBD-3) enhances the tight-junction (TJ) barrier function through CCR6. (a) Keratinocyte layers were pre-treated with 50mg ml1
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and the TER and the paracellular flux were measured. *Po0.05, **Po0.01, n¼5, compared with the nonstimulated cells, and between CCR6 siRNA-transfected
cells and control siRNA-transfected cells.
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(Wang et al., 2011) and a report that the PI3K inhibitors
attenuate the TER in response to prostaglandins (Little et al.,
2003). In addition, as the p85 subunit of PI3K binds to
occludin, this further suggests the importance of PI3K in TJ
tightening (Nusrat et al., 2000). However, the activation of the
PI3K cascade may also result in opposite effects on the TJ
barrier function, as PI3K is implicated in reduced TJ protein
expression upon treatment with HIV-1 Tat protein (Andras
et al., 2005) or TGFb1 (Bakin et al., 2000). Hence, further
studies are needed to fully clarify the role of the PI3K signaling
pathway in the TJ barrier function. Although other hBDs did
not affect keratinocyte layer permeability, they were able to
induce at some extent the activation of aPKC, Rac1, GSK-3,
and PI3K (Supplementary Figure S4 online). It seems that the
activation of above pathways by hBD-1, hBD-2, or hBD-4
does not affect the regulation of TJ function, but rather may be
involved in other activities such as cell survival, wound
healing, migration, or differentiation (Koivisto et al., 2003;
Efimova et al., 2004; Calautti et al., 2005; Tscharntke et al.,
2007), which are regulated by hBDs (Niyonsaba et al., 2009).
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Figure 5. Human b-defensin-3 (hBD-3) enhances the tight-junction (TJ) function through activation of atypical protein kinase C (aPKC)f/k and guanosine
triphosphate (GTP)-Rac1. Keratinocytes were incubated with 20mg ml 1 hBD-3, and lysates were separated by SDS-PAGE using antibodies against
phosphorylated aPKCz/l and aPKC (a), or quantified for GTP-Rac1 using a Rac1 activation assay kit (c). One representative experiment of three separate
experiments yielding similar results is shown. Keratinocyte layers were pre-treated with GF 109203X (b), NSC23766 (d), or 0.1% DMSO for 48 hours and
stimulated with 20mg ml 1 hBD-3 for 72 hours, and the transepithelial electrical resistance (TER) and paracellular flux were determined. The values obtained using
stimulated and nonstimulated cells or with the presence and absence of inhibitor were compared. *Po0.05, **Po0.01, ***Po0.001, n¼ 4.
C Kiatsurayanon et al.
Human b-Defensin-3 and Tight-Junction Barrier
www.jidonline.org 2169
Other possible TJ function regulators, including Toll-like
receptors, protein kinase A, and mitogen-activated protein
kinases, were also investigated, but failed to show that hBD-3
regulates the TJ barrier function through these components
(data not shown).
Collectively, we demonstrated that hBD-3 enhanced the
expression and cellular localization of selective TJ proteins,
and regulated the TJ barrier function. Therefore, in addition
to their antimicrobial and immunomodulatory functions,
we provide previously unreported evidence that HDPs also
contribute to the regulation of the skin barrier function.
MATERIALS AND METHODS
Reagents
Synthetic hBD-1 through hBD-4 were purchased from the Peptide
Institute (Osaka, Japan). Anti-claudin-1, claudin-3, and claudin-4 Abs
were from Invitrogen (Carlsbad, CA), whereas the anti-claudin-14 and
claudin-23 Abs were obtained from Abcam (Tokyo, Japan). Anti-
phosphorylated GSK-3a/b (Y279/Y216), aPKCz/l, and PI3K Abs, and
GSK-3a/b, aPKC, and PI3K Abs were from Cell Signaling Technology
(Beverly, MA). Anti-CCR6 antibody was from R&D Systems
(Minneapolis, MN). GF 109203X was purchased from Enzo Life
Sciences (Farmingdale, NY) and SB 415286 was from Tocris
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Figure 6. Human b-defensin-3 (hBD-3) enhances the tight-junction (TJ) function through glycogen synthase kinase-3 (GSK-3)a/b and phosphatidylinositol 3
kinase (PI3K) activation. Keratinocytes were incubated with 20mg ml1 hBD-3, and lysates were separated by SDS-PAGE using antibodies against phosphorylated
GSK-3a/b (Y279/Y216) and GSK-3a/b (a), or phosphorylated PI3K (p85/p55) and PI3K (c). The results of one representative experiment of the three separate
experiments yielding similar results are shown. Keratinocyte layers were pre-treated with SB 415286 (SB) (b), wortmannin (Wort) (d), or 0.1% DMSO for 48 hours
and stimulated with 20mg ml1 hBD-3 for 72 hours, and the transepithelial electrical resistance (TER) and paracellular flux were determined. The values obtained
using stimulated and nonstimulated cells or with the presence and absence of inhibitor were compared. *Po0.05, **Po0.01, ***Po0.001, n¼ 5.
C Kiatsurayanon et al.
Human b-Defensin-3 and Tight-Junction Barrier
2170 Journal of Investigative Dermatology (2014), Volume 134
Bioscience (Bristol, UK), whereas wortmannin and ochratoxin A were
obtained from Sigma-Aldrich (St Louis, MO). NSC23766 was
purchased from Calbiochem (La Jolla, CA).
Keratinocyte culture and stimulation
Keratinocytes purchased from Kurabo Industries (Osaka, Japan) were
cultured in HuMedia-KG2 (Kurabo Industries), as described pre-
viously (Niyonsaba et al., 2007). For total RNA extractions and
western blotting, the keratinocytes were cultured in 12-well plates
and incubated with peptides in HuMedia without supplements. For
the TER and paracellular flux assays, 0.72 105 cells were plated in
transwells with 0.4-mm pores (Millipore, Billerica, MA), and the
medium was replaced with high-Ca2þ (1.35 mM) medium after the
cells reached confluence.
Total RNA extraction and quantitative real-time reverse-
transcriptase–PCR
Total RNA extractions and quantitative real-time reverse-transcrip-
tase–PCR were performed as previously described (Niyonsaba et al.,
2007). mRNAs were amplified and quantitated using a StepOne
Plus Real-time PCR System (Applied Biosystems, Branchburg, NJ),
following the manufacturer’s instructions. The primer/probe sets used
were Applied Biosystems assays-on-demand products. The changes in
gene expression are reported as fold-increases relative to those of
untreated controls.
Western blot analysis
Keratinocytes were incubated with hBDs for the indicated periods.
After stimulation, the cells were lysed in radioimmunoprecipitation
assay buffer (Cell Signaling Technology) and equal amounts of lysate
proteins were subjected to 12.5% SDS-PAGE. The immunoblots were
incubated with appropriate Abs according to the manufacturer’s
instructions. The membranes were developed using Luminata Forte
Western HRP substrate (Millipore, Billerica, MA).
Measurements of TER and paracellular flux
Keratinocytes grown on 0.6-cm2 transwell filters were transferred into
the high-Ca2þ medium, and hBDs were added. The TER across the
keratinocyte layers was measured using a CellZscope (nanoAnalytics,
Mu¨nster, Germany) for 0–120 hours. Keratinocytes were also grown
on 0.3-cm2 transwell filters for the paracellular flux assay, which was
performed as described previously (Yuki et al., 2007), using 4 kDa
FITC–dextran (Sigma-Aldrich) as a tracer. Briefly, keratinocyte layers
were stimulated with hBDs for 0–120 hours, and the medium in the
apical and basal compartments was replaced with 250ml of P buffer
containing 10 mg ml 1 of FITC–dextran and 700ml of P buffer,
respectively. After 2 hours, the medium from the basal compartment
was collected and fluorescence was measured using a fluorimeter
(Nihon Molecular Devices, Tokyo, Japan). In some of the experi-
ments, the keratinocyte layers were pre-treated with specific inhibi-
tors or Abs, or transfected with CCR6 small interfering RNA
(Invitrogen) before stimulation, and the efficacy of knockdown was
confirmed by quantitative real-time reverse-transcriptase–PCR
(Supplementary Figure S3 online). Inhibitors used in this study had
no cytotoxicity as evaluated by trypan blue exclusion and lactate
dehydrogenase activity (data not shown). Following treatment,
keratinocyte layers were stimulated, and the TER and paracellular
flux assays were performed as above.
Rac1 activation assay
Keratinocytes grown in 12-well plates were stimulated with hBDs for
1–15 minutes. The cells were lysed in radioimmunoprecipitation
assay buffer supplemented with protease inhibitor cocktail, and
Rac1 activation in the lysates was determined using a Rac1 activation
assay kit (Cytoskeleton, Denver, CO), according to the manufacturer’s
recommendations.
Immunofluorescence microscopy
Keratinocytes were cultured on collagen I-coated chamber slides (BD
Biosciences, Bedford, MA) before fixation with methanol. Cells were
blocked in Protein Block Serum-Free (DakoCytomation, Carpentaria,
CA) containing 0.2% Tween-20, after which cells were incubated
overnight with the appropriate primary Abs in 1% BSA–PBS contain-
ing 0.2% Tween-20, followed by specific secondary Abs coupled to
Alexa 594 (Invitrogen). Images were captured using confocal laser
scanning microscopy (Carl Zeiss, Jena, Germany).
Statistical analysis
Statistical analysis was performed with an analysis of variance using
Prism GraphPad software (GraphPad Software, San Diego, CA).
Po0.05 was considered significant. The results are presented as the
mean values±SD.
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